Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Gui, Anping ^a   Kobayashi, Akira ^a   Motoyama, Hiroaki ^a   Kitazawa, Masato ^a   Takeoka, Michiko ^a   Miyagawa, Shinichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cholangiocarcinoma; Down regulation; EGFR; RBE cells; Recycling; Target; Tyrosine 1045

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAB11 PROTEIN; RAB11A PROTEIN; SMALL INTERFERING RNA; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CARCINOMA CELL; CELL IMMORTALIZATION; CELL STRAIN; CELL STRAIN MMNK 1; CELL STRAIN RBE; CELL SURFACE; CONTROLLED STUDY; ENDOSOME; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; LYSOSOME; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; UBIQUITINATION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; ENDOSOMES; EPIDERMAL GROWTH FACTOR; HUMANS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TYROSINE; UBIQUITINATION;

EID: 84860994366     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-179     Document Type: Article

References (44)

1. Friman S. Cholangiocarcinoma-current treatment options. Scand J Surg 2011, 100(1):30-34.
2. Jonas S, Thelen A, Benckert C, Biskup W, Neumann U, Rudolph B, Lopez-Häänninen E, Neuhaus P. Extended liver resection for intrahepatic cholangiocarcinoma: A comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Ann Surg 2009, 249(2):303-309. 10.1097/SLA.0b013e318195e164, 19212186.
3. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008, 98(2):418-425. 10.1038/sj.bjc.6604129, 2361442, 18087285.
4. Nakazawa K, Dobashi Y, Suzuki S, Fuji H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB 2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005, 206(3):356-365. 10.1002/path.1779, 15892172.
5. Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 2005, 131(10):649-652. 10.1007/s00432-005-0016-1, 16032426.
6. Chang PY, Cheng MF, Lee HS, Hsieh CB, Yao NS. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie 2010, 33(1-2):45-47.
7. Yabuuchi S, Katayose Y, Oda A, Mizuma M, Shirasou S, Sasaki T, Yamamoto K, Oikawa M, Rikiyama T, Onogawa T, Yoshida H, Ohtuska H, Motoi F, Egawa S, Unno M. ZD1839 (IRRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines. Anticancer Res 2009, 29(4):1169-1180.
8. Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C, Bralet MP. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 2007, 72(1-2):105-110.
9. Wells A. EGF receptor. Int J Biochem Cell Biol 1999, 31(6):637-643. 10.1016/S1357-2725(99)00015-1, 10404636.
10. Yarden Y. The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(suppl 4):S3-S8.
11. Fichera A, Little N, Jagadeeswaran S, Dougherty U, Sehdev A, Mustafi R, Cerda S, Yuan W, Khare S, Tretiakova M, Gong C, Tallerico M, Cohen G, Joseph L, Hart J, Turner JR, Bissonnette M. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res 2007, 67(2):827-835. 10.1158/0008-5472.CAN-05-3343, 2705749, 17234795.
12. Holz C, Niehr F, Boyko M, Hristozova T, Distel L, Budach V, Tinhofer I. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiother Oncol 2011, 101(1):158-164. 10.1016/j.radonc.2011.05.042, 21665310.
13. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanism for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007, 19(10):2013-2023. 10.1016/j.cellsig.2007.06.023, 17681753.
14. Sorkin A, von Zastrow M. Endocytosis and signaling: intertwining molecular networks. Nat Rev Mol Cell Biol 2009, 10(9):609-622. 10.1038/nrm2748, 2895425, 19696798.
15. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Maddhus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002, 156(5):843-854. 10.1083/jcb.200106056, 2173306, 11864992.
16. Jiang X, Huang F, Marusyk A, Sorkin A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 2003, 14(3):858-870. 10.1091/mbc.E02-08-0532, 151565, 12631709.
17. Stang E, Blystad FD, Kazazic M, Bertelsen V, Brodahl T, Raiborg C, Stenmark H, Madshus IH. Cbl-dependent ubiquitination is required for progression of EGF receptors into clathrin-coated pits. Mol Biol Cell 2004, 15(8):3591-3604. 10.1091/mbc.E04-01-0041, 491821, 15194809.
18. Ravid T, Heidinger JM, Gee P, Khan EM, Goldkorn T. c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J Biol Chem 2004, 279(35):37153-37162. 10.1074/jbc.M403210200, 15210722.
19. Umebayashi K, Stenmark H, Yoshimori T. Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation. Mol Biol Cell 2008, 19(8):3454-3462. 10.1091/mbc.E07-10-0988, 2488299, 18508924.
20. Visser-Smit GD, Place TL, Cole SL, Clausen KA, Vemuganti S, Zhang G, Koland JG, Lill NL. Cbl controls EGFR fate by regulating early endosome fusion. Sci Signal 2009, 2(102):ra86. 10.1126/scisignal.2000217, 2813709, 20029031.
21. Maruyama M, Kobayashi N, Westerman KA, Sakaguchi M, Allain JE, Totsugawa T, Okitsu T, Fukazawa T, Weber A, Stolz DB, Leboulch P, Tanaka N. Establishment of a highly differentiated immortalizaed human cholangiocyte cell line with SV40T and hTERT. Transplantation 2004, 77(3):446-451. 10.1097/01.TP.0000110292.73873.25, 14966424.
22. Kitahara H, Masumoto J, Parker AL, Maruta F, Kubo N, Shimizu A, Akita N, Miwa S, Kobayashi N, Nakayama J, Miyagawa S. COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78. Mol Cancer Res 2011, 9(6):688-701. 10.1158/1541-7786.MCR-10-0470, 21571834.
23. Ravid T, Sweeney C, Gee P, Carraway KL, Goldkorn T. Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation. J Biol Chem 2002, 277(34):31214-31219. 10.1074/jbc.M204677200, 12063263.
24. Chung BM, Raja SM, Clubb RJ, Tu C, George M, Band V, Band H. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol 2009, 10:84. 10.1186/1471-2121-10-84, 2790444, 19948031.
25. Lill NL, Douillard P, Awwas RA, Ota S, Lupher ML, Miyake S, Meissner-Lula N, Hsu VW, Band H. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem 2000, 275(1):367-377. 10.1074/jbc.275.1.367, 10617627.
26. Lu A, Tebar F, Alvarez-Moya B, Lopez-Alcala C, Calvo M, Enrich C, Agell N, Nakamura T, Matsuda M, Bachs O. A clathrin-dependent pathway leads to KRas signaling on late endosomes en route to lysosome. J Cell Biol 2009, 184(6):863-879. 10.1083/jcb.200807186, 2699148, 19289794.
27. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH, Cox NJ, Bates SE, Ratain MJ. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in NCI60 cell lines. Clin Cancer Res 2007, 13(22 Pt 1):6788-6795.
28. Wilson GM, Fielding AB, Simon GC, Yu X, Andrews PD, Hames RS, Frey AM, Peden AA, Gould GW, Prekeris R. The FIP-Rab11 protein complex regulates recycling endosome targeting to the cleavage furrow during late cytokinesis. Mol Biol Cell 2005, 16(2):849-860. 545916, 15601896.
29. de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J. c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci 2001, 114(Pt 11):2167-2178.
30. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008, 314(17):3093-3106. 2605728, 18793634.
31. Waterman H, Levkowitz G, Alroy I, Yarden Y. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem 1999, 274(32):22151-22154. 10.1074/jbc.274.32.22151, 10428778.
32. Padrón D, Sato M, Shay JW, Gazdar AF, Minna JD, Roth MG. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Cancer Res 2007, 67(16):7695-7702. 10.1158/0008-5472.CAN-07-0484, 2852256, 17699773.
33. VanMeter AJ, Rodriguez AS, Bowman ED, Jen J, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF, Liotta LA, Espina V. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGFR) phosphorylation events associated with mutanted EGFR compared with wild type. Mol Cell Proteomics 2008, 7(10):1902-1924. 10.1074/mcp.M800204-MCP200, 2559935, 18687633.
34. Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 2006, 21(6):737-748. 10.1016/j.molcel.2006.02.018, 16543144.
35. Klein P, Mattoon D, Lemmon MA, Schlessinger J. A structure-based model for ligand binding and dimerization of EGF receptors. Proc Natl Acad Sci U S A 2004, 101(4):929-934. 10.1073/pnas.0307285101, 327119, 14732694.
36. Maegawa M, Arao T, Yokote H, Matsumoto K, Kudo K, Tanaka K, Kaneda H, Tujita Y, Ito F, Nishio K. Epidermal growth factor receptor lacking C-terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factoe receptor tyrosine kinase inhibitor. Cancer Sci 2009, 100(3):552-557. 10.1111/j.1349-7006.2008.01071.x, 19154417.
37. Grøvdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004, 300(2):388-395. 10.1016/j.yexcr.2004.07.003, 15475003.
38. Han W, Zhang T, Yu H, Foulke JG, Tang CK. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFR vIII. Cancer Biol Ther 2006, 5(10):1361-1368. 10.4161/cbt.5.10.3226, 16969069.
39. Willmarth NE, Baillo A, Dziubinski ML, Wilson K, Riese DJ, Ethier SP. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR loop. Cell Signal 2009, 21(2):212-219. 10.1016/j.cellsig.2008.10.003, 2632975, 18951974.
40. Davis RJ. Independent mechanisms account for the regulation by protein kinase C of the epidermal growth factor receptor affinity and tyrosine-protein kinase activity. J Biol Chem 1988, 263(19):9462-9469.
41. Davis RJ, Czech MP. Stimulation of epidermal growth factor receptor threonine 654 phosphorylation by platelet-derived growth factor in protein kinase C-deficient human fibroblasts. J Bio Chem 1987, 262(14):6832-6841.
42. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal factor by inhibiting endosome recycling. Proc Natl Acad Sci U S A 2010, 107(30):13252-13257. 10.1073/pnas.0913476107, 2922117, 20616078.
43. Ren M, Xu G, Zeng J, De Lemos-Chiarandini C, Adesnik M, Sabatini DD. Hydrolysis of GTP on rab11 is required for the direct delivery of transferrin from the pericentriolar recycling compartment to the cell surface but not from sorting endosomes. Proc Natl Acad Sci U S A 1998, 95(11):6187-6192. 10.1073/pnas.95.11.6187, 27621, 9600939.
44. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004, 5(2):121-132. 10.1038/nrm1315, 15040445.